{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:59:37Z","timestamp":1782331177649,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11154-021-09649-x","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:02:35Z","timestamp":1617649355000},"page":"147-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly"],"prefix":"10.1007","volume":"22","author":[{"given":"Giovanni","family":"Tulipano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"9649_CR1","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1101\/gad.1599207","volume":"21","author":"N Mizushima","year":"2007","unstructured":"Mizushima N. Autophagy: process and function. Genes Dev. 2007;21:2861\u201373.","journal-title":"Genes Dev"},{"key":"9649_CR2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","volume":"7182","author":"N Mizushima","year":"2008","unstructured":"Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;7182:1069\u201375.","journal-title":"Nature"},{"key":"9649_CR3","doi-asserted-by":"crossref","unstructured":"Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004; 306: 990\u2013995.","DOI":"10.1126\/science.1099993"},{"issue":"1793","key":"9649_CR4","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.bbamcr.2009.01.006","volume":"2009","author":"E Morselli","year":"2009","unstructured":"Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, Kroemer G. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta. 2009;2009(1793):1524\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"9649_CR5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ncb2788","volume":"15","author":"P Boya","year":"2013","unstructured":"Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol. 2013;15:713\u201320.","journal-title":"Nat Cell Biol"},{"key":"9649_CR6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/med.21531","volume":"39","author":"H Folkerts","year":"2019","unstructured":"Folkerts H, Hilgendorf S, Vallenga E, Bremer E, Wiersma VR. The multifaceted role of autophagy in cancer and the microenvironment. Med Res Rev. 2019;39:517\u201360.","journal-title":"Med Res Rev"},{"key":"9649_CR7","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/ERC-15-0042","volume":"22","author":"A Weckman","year":"2015","unstructured":"Weckman A, Rotondo F, Di Ieva A, Syro LV, Butz H, Cusimano MD, Kovacs K. Autophagy in endocrine tumors. Endocr Relat Cancer. 2015;22:R205\u201318.","journal-title":"Endocr Relat Cancer"},{"key":"9649_CR8","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.3390\/ijms19113466","volume":"19","author":"CW Yun","year":"2018","unstructured":"Yun CW, Lee SH. The roles of autophagy in cancers. Int J Mol Sci. 2018;19:3466.","journal-title":"Int J Mol Sci"},{"key":"9649_CR9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","volume":"140","author":"N Mizushima","year":"2010","unstructured":"Mizushima N, Yoshimori T, Levine B. Methods in Mammalian Autophagy Research. Cell. 2010;140:313\u201324.","journal-title":"Cell"},{"key":"9649_CR10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4161\/auto.19496","volume":"84","author":"DJ Klionski","year":"2012","unstructured":"Klionski DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;84:445\u2013544.","journal-title":"Autophagy"},{"key":"9649_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/JME-13-0241","volume":"52","author":"A Weckman","year":"2014","unstructured":"Weckman A, Di Ieva A, Rotondo F, Syro LV, Ortiz LD, Kovacs K, Cusimano MD. Autophagy in the endocrine glands. J Mol Endocrinol. 2014;52:151\u201363.","journal-title":"J Mol Endocrinol"},{"key":"9649_CR12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1210\/en.2015-1777","volume":"157","author":"ME Mercau","year":"2016","unstructured":"Mercau ME, Repetto EM, Perez MN, Martinez Calejman C, Sanchez Puch S, Finkielstein CV, Cymeryng CB. Moderate Exercise Prevents Functional Remodeling of the Anterior Pituitary Gland in Diet-Induced Insulin Resistance in Rats: Role of Oxidative Stress and Autophagy. Endocrinology. 2016;157:1135\u201345.","journal-title":"Endocrinology"},{"key":"9649_CR13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-981-15-4272-5_12","volume":"1207","author":"Z Wu","year":"2020","unstructured":"Wu Z, Gu W. Autophagy and pituitary adenoma. Adv Exp Med Biol. 2020;1207:183\u201394.","journal-title":"Adv Exp Med Biol"},{"key":"9649_CR14","unstructured":"Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity.  Am J Pathol. 1978;64: 492\u2013499."},{"key":"9649_CR15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0026-0495(82)90184-6","volume":"31","author":"K Mashiter","year":"1982","unstructured":"Mashiter K, De Marco L, Van Noorden S, Adams E, Loizou M, Joplin GF, Peters TJ. Inappropriately low serum GH in an acromegalic: lysosomal involvement in intracellular hormone degradation. Metabolism. 1982;31:931\u20136.","journal-title":"Metabolism"},{"key":"9649_CR16","doi-asserted-by":"crossref","unstructured":"Kovacs K, Horvath E, Ilse RG, Ezrin C, Ilse D. Spontaneous pituitary adenomas in aging rats. A light microscopic, immunocytological and fine structural study. Beitrage zur Pathologie. 1977;161: 1\u201316.","DOI":"10.1016\/S0005-8165(77)80106-6"},{"key":"9649_CR17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.1987.tb00796.x","volume":"26","author":"SR George","year":"1987","unstructured":"George SR, Kovacs K, Asa SL, Horvath E, Cross EG, Burrow GN. Effect of SMS 201\u2013995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma. Clin Endocrinol. 1987;26:395\u2013405.","journal-title":"Clin Endocrinol"},{"key":"9649_CR18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-0042-107243","volume":"126","author":"FK Dagistanli","year":"2018","unstructured":"Dagistanli FK, Ozkaya HM, Kucukyoruk B, Biceroglu H, Metin D, Gazioglu N, et al. Preoperative Somatostatin Analogue Treatment Might Trigger Apoptosis and Autophagy in Tumor Tissues of Patients with Acromegaly: A Pilot Study. Exper Clin Endocrinol Diab. 2018;126:168\u201375.","journal-title":"Exper Clin Endocrinol Diab"},{"key":"9649_CR19","doi-asserted-by":"crossref","first-page":"39329","DOI":"10.18632\/oncotarget.5744","volume":"17","author":"SJ Lin","year":"2015","unstructured":"Lin SJ, Leng ZG, Guo YH, Cai L, Cai Y, Li N, et al. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline. Oncotarget. 2015;17:39329\u201341.","journal-title":"Oncotarget"},{"key":"9649_CR20","doi-asserted-by":"crossref","unstructured":"Zhang K, Yang Y, Wang D, Xie B, Li X, Xu B. HIF-I alpha inhibition sensitized pituitary adenoma cells to temozolomide by regulating presenilin I expression and autophagy. Technol Cancer Res T. 2016; 15: NP95\u2013104.","DOI":"10.1177\/1533034615618834"},{"key":"9649_CR21","doi-asserted-by":"crossref","first-page":"19749","DOI":"10.1002\/jcb.29281","volume":"120","author":"A Coker-Gurkan","year":"2019","unstructured":"Coker-Gurkan A, Ayhan-Sahin B, Keceloglu G, Obakan-Yerlikaya P, Arisan ED, Palavan-Unsal N. Atiprimod induce apoptosis in pituitary adenoma: Endoplasmic reticulum stress and autophagy pathways. J Cell Biochem. 2019;120:19749\u201363.","journal-title":"J Cell Biochem"},{"key":"9649_CR22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fendo.2019.00690","volume":"10","author":"N Li","year":"2019","unstructured":"Li N, Zhan X. Mitochondria dysfunction pathway networks and mitochondria dynamics in the pathogenesis of pituitary adenomas. Front Endocrinol. 2019;10:690.","journal-title":"Front Endocrinol"},{"key":"9649_CR23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2018.05.041","volume":"295","author":"H Deyu","year":"2018","unstructured":"Deyu H, Luqing C, Xianglian L, Pu G, Qirong L, Xu W, et al. Protective mechanisms involving enhanced mitochondrial functions and mitophagy against T-2 toxin-induced toxicities in GH3 cells. Toxicol Lett. 2018;295:41\u201353.","journal-title":"Toxicol Lett"},{"key":"9649_CR24","doi-asserted-by":"publisher","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab. 2020; 105: https:\/\/doi.org\/10.1210\/clinem\/dgz096.","DOI":"10.1210\/clinem\/dgz096"},{"key":"9649_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09564-7","author":"P Mortini","year":"2020","unstructured":"Mortini P, Nocera G, Roncelli F, Losa M, Formenti AM, Giustina A. The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective. Rev Endocr Metab Disord. 2020. https:\/\/doi.org\/10.1007\/s11154-020-09564-7.","journal-title":"Rev Endocr Metab Disord"},{"key":"9649_CR26","first-page":"20","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R. Acromegaly Nat Rev Dis. 2019;5:20.","journal-title":"Acromegaly Nat Rev Dis"},{"key":"9649_CR27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","volume":"37","author":"T Mancini","year":"2008","unstructured":"Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008;37:67\u201399.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"9649_CR28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000054651","volume":"73","author":"G Tulipano","year":"2001","unstructured":"Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology. 2001;73:344\u201351.","journal-title":"Neuroendocrinology"},{"key":"9649_CR29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11102-010-0269-9","volume":"14","author":"A Giustina","year":"2011","unstructured":"Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KKY, et al. Current management practices for acromegaly: an international survey. Pituitary. 2011;14:125\u201333.","journal-title":"Pituitary"},{"key":"9649_CR30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","volume":"138","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A. The modern criteria for medical management of acromegaly. Prog Mol Biol Transl Sci. 2016;138:63\u201383.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"9649_CR31","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly. PlosOne. 2012;7:e36411.","journal-title":"PlosOne"},{"key":"9649_CR32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","volume":"13","author":"G Mazziotti","year":"2010","unstructured":"Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13:60\u20137.","journal-title":"Pituitary"},{"key":"9649_CR33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161:331\u20138.","journal-title":"Eur J Endocrinol"},{"key":"9649_CR34","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","volume":"102","author":"A Giustina","year":"2017","unstructured":"Giustina A, Mazziotti G, Cannav\u00f2 S, Castello R, Arnaldi G, Bugari G, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab. 2017;102:2454\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"9649_CR35","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/14656566.2016.1199687","volume":"17","author":"F Maffezzoni","year":"2016","unstructured":"Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A. Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother. 2016;17:1631\u201342.","journal-title":"Expert Opin Pharmacother"},{"key":"9649_CR36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","volume":"179","author":"P Brazeau","year":"1973","unstructured":"Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77\u20139.","journal-title":"Science"},{"key":"9649_CR37","doi-asserted-by":"crossref","unstructured":"G\u00fcnther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev. 2018; 70: 763\u2013835.","DOI":"10.1124\/pr.117.015388"},{"key":"9649_CR38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1471-4159.2004.02402.x","volume":"89","author":"G Olias","year":"2004","unstructured":"Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem. 2004;89:1057\u201391.","journal-title":"J Neurochem"},{"key":"9649_CR39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157\u201398.","journal-title":"Front Neuroendocrinol"},{"key":"9649_CR40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","volume":"152","author":"U Rai","year":"2015","unstructured":"Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: current view and potential applications. Pharmacol Ther. 2015;152:98\u2013110.","journal-title":"Pharmacol Ther"},{"key":"9649_CR41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11102-020-01028-0","volume":"23","author":"G Tulipano","year":"2020","unstructured":"Tulipano G, Giustina A. Effects of octreotide on autophagy markers and cell viability markers related to metabolic activity in rat pituitary tumor cells. Pituitary. 2020;23:223\u201331.","journal-title":"Pituitary"},{"key":"9649_CR42","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1167\/iovs.16-19285","volume":"57","author":"R Amato","year":"2016","unstructured":"Amato R, Biagioni M, Cammalleri M, Dal Monte M, Casini G. VEGF as a Survival Factor in Ex Vivo Models of Early Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2016;57:3066\u201376.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9649_CR43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.phrs.2017.09.022","volume":"128","author":"R Amato","year":"2018","unstructured":"Amato R, Catalani E, Dal Monte M, Cammalleri M, Di Renzo I, Perrotta C, et al. Autophagy-mediated neuroprotection induced by octreotide in an ex vivo model of early diabetic retinopathy. Pharmacol Res. 2018;128:167\u201378.","journal-title":"Pharmacol Res"},{"key":"9649_CR44","doi-asserted-by":"crossref","first-page":"42701","DOI":"10.1038\/srep42701","volume":"7","author":"H Sun","year":"2017","unstructured":"Sun H, Zou S, Candiotti KA, Peng Y, Zhang Q, Xiao W, et al. Octreotide Attenuates Acute Kidney Injury after Hepatic Ischemia and Reperfusion by Enhancing Autophagy. Sci Rep. 2017;7:42701.","journal-title":"Sci Rep"},{"key":"9649_CR45","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.transproceed.2013.02.112","volume":"45","author":"J Yang","year":"2013","unstructured":"Yang J, Sun H, Takacs P, Zhang Y, Liu J, Chang Y, Candiotti KA. The effect of octreotide on hepatic ischemia-reperfusion injury in a rabbit model. Transplant Proc. 2013;45:2433\u20138.","journal-title":"Transplant Proc"},{"key":"9649_CR46","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1159\/000493413","volume":"49","author":"Y Li","year":"2018","unstructured":"Li Y, Wang S, Gao X, Zhao Y, Li Y, Yang B, Zhang N, Mah L. Octreotide alleviates autophagy by up-regulation of microRNA 101 in intestinal epithelial cell line Caco-2. Cell Physiol Biochem. 2018;49:1352\u201363.","journal-title":"Cell Physiol Biochem"},{"key":"9649_CR47","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1\u201324.","journal-title":"Eur J Endocrinol"},{"key":"9649_CR48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11154-019-09531-x","volume":"21","author":"L Kasuki","year":"2020","unstructured":"Kasuki L, Raverot G. Definition and diagnosis of aggressive pituitary tumors. Rev Endocr Metab Disord. 2020;21:203\u20138.","journal-title":"Rev Endocr Metab Disord"},{"key":"9649_CR49","doi-asserted-by":"crossref","first-page":"608422","DOI":"10.3389\/fendo.2020.608422","volume":"11","author":"C Dai","year":"2020","unstructured":"Dai C, Liang S, Sun B, Kang J. The progress of immunotherapy in refractory pituitary adenomas andpituitary carcinomas. Front Endocrinol. 2020;11:608422.","journal-title":"Front Endocrinol"},{"key":"9649_CR50","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/jc.2015-3653","volume":"101","author":"S Melmed","year":"2016","unstructured":"Melmed S. Pituitary medicine from discovery to patient-focused outcomes. J Clin Endocrinol Metab. 2016;101:769\u201377.","journal-title":"J Clin Endocrinol Metab"},{"key":"9649_CR51","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21:667\u201378.","journal-title":"Rev Endocr Metab Disord"},{"key":"9649_CR52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","volume":"100","author":"D Cuevas-Ramos","year":"2015","unstructured":"Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100:122\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"9649_CR53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65:265\u201373.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9649_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-019-01025-y","volume":"23","author":"S Petersenn","year":"2020","unstructured":"Petersenn S, Giustina A. Diagnosis and management of prolactinomas: current challenges. Pituitary. 2020;23:1\u20132.","journal-title":"Pituitary"},{"key":"9649_CR55","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1080\/15548627.2017.1328347","volume":"13","author":"ZG Leng","year":"2017","unstructured":"Leng ZG, Lin SJ, Wu ZR, Guo YH, Cai L, Shang HB, et al. Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophaguc cell death. Autophagy. 2017;13:1404\u201319.","journal-title":"Autophagy"},{"key":"9649_CR56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2019.05.043","volume":"459","author":"H Yao","year":"2019","unstructured":"Yao H, Tang H, Zhang Y, Zhang QF, Liu XY, Liu YT, et al. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma. Cancer Lett. 2019;459:135\u201344.","journal-title":"Cancer Lett"},{"key":"9649_CR57","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1210\/jc.2017-00627","volume":"102","author":"SJ Lin","year":"2017","unstructured":"Lin SJ, Wu ZR, Cao L, Zhang Y, Leng ZG, Guo YH, et al. Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine. J Clin Endocrinol Metab. 2017;102:3692\u2013703.","journal-title":"J Clin Endocrinol Metab"},{"key":"9649_CR58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fendo.2018.00318","volume":"9","author":"LV Syro","year":"2018","unstructured":"Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K. Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. Front Endocrinol. 2018;9:318.","journal-title":"Front Endocrinol"},{"key":"9649_CR59","doi-asserted-by":"crossref","unstructured":"Wang C, Tan C, wen Y, Zhang D, Li G, Chang L et al. FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt\/\u03b2-catenin signaling pathway. Cell Death and Disease 2019; 10: 499.","DOI":"10.1038\/s41419-019-1694-y"},{"key":"9649_CR60","doi-asserted-by":"crossref","first-page":"12291","DOI":"10.1038\/srep12291","volume":"5","author":"H-M Wu","year":"2015","unstructured":"Wu H-M, Jiang Z-F, Ding P-S, Shao L-J, Liu R-Y. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Sci Rep. 2015;5:12291.","journal-title":"Sci Rep"},{"key":"9649_CR61","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.3892\/mmr.2015.4255","volume":"12","author":"H Wu","year":"2015","unstructured":"Wu H, Huang S, Chen Z, Liu W, Zhou X, Zhang D. Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1\u03b1\/BNIP3 signaling pathway. Mol Med Rep. 2015;12:6467\u201374.","journal-title":"Mol Med Rep"},{"key":"9649_CR62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1385\/EP:16:2:123","volume":"16","author":"D Yoshida","year":"2005","unstructured":"Yoshida D, Kim K, Yamazaki M, Teramoto A. Expression of hypoxia-inducible-factor-1alpha and cathepsin D in pituitary adenomas. Endocr Pathol. 2005;16:123\u201331.","journal-title":"Endocr Pathol"},{"key":"9649_CR63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1385\/EP:16:2:115","volume":"16","author":"K Kim","year":"2005","unstructured":"Kim K, Yoshida D, Teramoto A. Expression of hypoxia-inducible-factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol. 2005;16:115\u201321.","journal-title":"Endocr Pathol"},{"key":"9649_CR64","doi-asserted-by":"crossref","unstructured":"Ribatti D, Conconi MT, Nussdorfer GG. Nonclassical endogenous novel regulators of angiogenesis. Pharmacol Rev. 2007; 59: 185\u2013205 (corrected in Pharmacol. Rev. 59, 288).","DOI":"10.1124\/pr.59.2.3"},{"key":"9649_CR65","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","volume":"66","author":"M Theodoropoulou","year":"2006","unstructured":"Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, et al. Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression. Cancer Res. 2006;66:1576\u201382.","journal-title":"Cancer Res"},{"key":"9649_CR66","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1042\/BCJ20160780","volume":"474","author":"B Carroll","year":"2017","unstructured":"Carroll B, Dunlop EA. The lysosome: a crucial hub for AMPK and mTORC1 signalling. Biochem J. 2017;474:1453\u201366.","journal-title":"Biochem J"},{"key":"9649_CR67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fendo.2019.00007","volume":"10","author":"Q Yang","year":"2019","unstructured":"Yang Q, Li X. Molecular network basis of invasive pituitary adenoma: a review. Front Endocrinol. 2019;10:7.","journal-title":"Front Endocrinol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09649-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-021-09649-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09649-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T07:09:07Z","timestamp":1619766547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-021-09649-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9649"],"URL":"https:\/\/doi.org\/10.1007\/s11154-021-09649-x","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"22 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"G.T. and A.G. have received research grants from Novartis Farma Spa.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}